Conference
Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Abstract
The prognostic values of p53 and of its downstream mediator p21WAF1/Cip1 in patients receiving adjuvant chemotherapy for epithelial ovarian cancer have not been clearly established. Tumor extracts from a series of 120 patients treated postsurgically with cisplatin or carboplatin alone or together with other chemotherapeutics for primary ovarian carcinoma were assayed both for p53 protein by an immunofluorometric assay developed by us and for …
Authors
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Volume
6
Pagination
pp. 3260-3270
Publication Date
August 2000
Conference proceedings
Clinical Cancer Research
Issue
8
ISSN
1078-0432
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemotherapy, AdjuvantCisplatinCyclin-Dependent Kinase Inhibitor p21CyclinsDisease-Free SurvivalDose-Response Relationship, DrugFemaleHumansImmunoassayMiddle AgedNeoplasm StagingOvarian NeoplasmsProportional Hazards ModelsSurvival AnalysisTissue DistributionTumor Suppressor Protein p53